QDEL earnings analysis
What we found in QDEL's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
QuidelOrtho reported Q1 2026 revenue of $619.8 million, missing analyst estimates of $650.95 million, representing an 11% decline year-over-year. Diluted EPS showed a loss of $0.04, far worse than the expected gain of $0.41, indicating significant operational challenges amid headwinds from reduced sales of respiratory products and geopolitical tensions affecting their revenue streams.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Decline of 11% YoY
- Total revenue decreased to $619.8 million, down from $692.8 million in the same quarter last year, primarily due to reduced demand for respiratory products.
- Operating Margin Improvement
- Operating margin improved slightly to -9.3%, from -14.2% in the previous quarter, indicating some operational efficiency gains despite revenue challenges.
- Immunohematology Segment Growth
- Immunohematology revenues increased by 8% to $138.3 million, primarily driven by reagent growth.
- Debt Capitalization Update
- Total debt remains significant with a Credit Agreement totaling $3.45 billion, representing ongoing financial commitments as management navigates through a challenging market.
- Cash From Financing Activities
- Cash provided by financing activities was $37.6 million, primarily related to net proceeds from the Revolving Credit Facility.
- Liquidity Position
- As of March 29, 2026, cash and cash equivalents were $140.4 million, down $29.4 million from the previous quarter.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Weaker Demand for Respiratory Products
- Sales of respiratory products decreased significantly, contributing directly to revenue loss; respiratory products accounted for only 11% of total revenues in Q1 2026 vs 17% in Q1 2025.
- Headwinds from Geopolitical Tensions
- Ongoing conflicts in the Middle East have caused delays in EMEA orders, which may affect future revenue and stability.
- Ongoing Tariff Impact
- Rising political tensions and trade tariffs have led to increased operating costs, potentially undermining profit margins in the future.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.04
- Gross margin
- 42.6%
- Operating margin
- -9.3%
- Segment
- Labs
- Segment
- Immunohematology
- Segment
- Point of Care
- Segment
- Molecular Diagnostics
- Segment
- Donor Screening
What they said about what is next.
Updated guidance reflects lower revenue and adjusted EBITDA expectations based on current market dynamics.
The filing reads worse than the one before it.
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing QDEL makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever